COO vs NBIX
Cooper Companies (The) vs Neurocrine Biosciences — AI-powered side-by-side comparison
COO
Cooper Companies (The)
67
Buy
VS
NBIX
Neurocrine Biosciences
63
Buy
| Metric | COO | NBIX |
|---|
| AI Score |
67
|
63
|
| Price |
$76.31
|
$164.93
|
| P/E Ratio |
62.91×
|
23.18×
|
| ROE |
4.6%
|
14.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
64.4%
|
98.0%
|
| Debt / Equity |
0.30×
|
0.11×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
61.8
|
37.5
|
| Beta |
0.823
|
0.394
|
| Expected Upside |
+0.2%
|
—
|
AI Committee View
Current Innellis committee reasoning for COO versus NBIX.
COO leads by 4 points.
COO scores 67/100 (Buy) versus NBIX at 63/100 (Buy).
COO Committee View
75% agreement
4 analysts
The primary driver is 4 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Risk/reward is unfavorable: 4.4% downside vs 0.2% upside.
NBIX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 21.1% shows genuine earnings power backing the valuation — Value
- Revenue growing 34.4% YoY -- genuine top-line momentum — Growth
- EPS growing 101.3% YoY — Growth
Bear Case
- Price-to-book of 4.3x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 16.0% signals elevated volatility — Risk